PHAT PEER ANALYSIS

Phathom Pharmaceuticals Inc — metric-by-metric comparison with peers and the industry median

PHATPhathom Pharmaceuticals Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile

PHATIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year

Split-adjusted

Year-to-Date (YTD)

Key Metric Comparison

P/E

Lower is better

ROE

Higher is better

Net Margin

Higher is better

Revenue Growth

Higher is better

All Metrics

Valuation
Metric	PHAT	MSB	TLX	RTALB	CSL	Ind. Median
P/E	—	—	—	4.89●	29.44	17.91
P/B	-2.73●	—	6.37	0.61	2.20	3.51
EV/EBITDA	—	—	120.14	74.61	10.21●	14.82
P/S	4.49	31.61	3.24	6.67	2.62●	10.89

Financial Health
Metric	PHAT	MSB	TLX	RTALB	CSL	Ind. Median
Current Ratio	2.21	—	1.43	1.21	2.57●	5.90
Debt/Equity	-49.4%●	—	112.3%	1.2%	67.4%	10.9%
NetDebt/EBITDA	0.16●	—	13.13	0.90	2.22	1.15

Profitability
Metric	PHAT	MSB	TLX	RTALB	CSL	Ind. Median
Net Margin	-76.8%	-115.3%	-0.9%	136.3%●	9.2%	-125.7%
ROE	—	-11.3%	-1.8%	15.1%●	7.7%	-47.5%
ROA	-52.5%	-8.6%	-0.7%	13.1%●	3.8%	-35.8%
EBITDA Margin	-44.4%	-76.6%	3.0%	9.0%	32.8%●	-105.8%

Growth + Dividend
Metric	PHAT	MSB	TLX	RTALB	CSL	Ind. Median
Rev. Growth	150.3%	410.4%●	56.3%	24.0%	4.8%	5.1%
NI Growth	—	—	—	134.0%●	-39.4%	12.1%
Div. Yield	—	0.0%	—	0.0%	2.5%●	0.2%
Payout	—	0.0%	—	0.0%	103.1%	0.0%

Valuation
Metric	PHAT	GERN	LXRX	ABUS	FDMT	MRVI	Ind. Median
P/E	—	—	—	5.92	—	—	17.91
P/B	-2.73●	3.97	4.58	3.65	1.96	4.18	3.51
EV/EBITDA	—	—	—	5.32	—	—	14.82
P/S	4.49	4.64	13.33	4.97	10.03	4.32●	10.89

Financial Health
Metric	PHAT	GERN	LXRX	ABUS	FDMT	MRVI	Ind. Median
Current Ratio	2.21	6.78	18.79	54.26●	9.34	5.91	5.90
Debt/Equity	-49.4%●	109.9%	28.4%	0.2%	4.5%	128.0%	10.9%
NetDebt/EBITDA	0.16	1.69	6.48	-0.59	2.27	-1.01●	1.15

Profitability
Metric	PHAT	GERN	LXRX	ABUS	FDMT	MRVI	Ind. Median
Net Margin	-76.8%	-35.5%	-37.5%	84.0%●	-182.3%	-51.1%	-125.7%
ROE	—	-28.0%	-16.0%	94.7%●	-34.9%	-40.8%	-47.5%
ROA	-52.5%	-12.7%	-9.2%	81.5%●	-31.3%	-12.5%	-35.8%
EBITDA Margin	-44.4%	-18.8%	-25.0%	84.0%●	-185.2%	-50.8%	-105.8%

Growth + Dividend
Metric	PHAT	GERN	LXRX	ABUS	FDMT	MRVI	Ind. Median
Rev. Growth	150.3%	68.6%	123.1%	2,889.9%	383,560.9%●	-15.4%	5.1%
NI Growth	—	—	—	—	—	—	12.1%
Div. Yield	—	—	—	—	—	—	0.2%
Payout	—	—	—	—	—	—	0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on PHAT

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 6, 26. This content is for informational purposes only and is not investment advice.